Company intelligence / Profile preview
ZaBeCor Pharmaceutical
Bala Cynwyd, Pennsylvania, United States
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
ZaBeCor developed Excellair, an inhaled siRNA silencing Syk kinase for asthma and inflammation. Early clinical results showed safety and tolerability at daily inhaled doses in phase I and II trials. No major clinical advances or recent trials reported after early 2010s.
- Therapeutic areas
- HematologyImmunologyInfectious DiseasesPulmonologyOphthalmology
- Modalities
- Small interfering RNA (siRNA)Antisense oligonucleotideSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Licensing agreement with Acuity Pharmaceuticals for Excellair ophthalmic applications
Beyond the preview
Go deeper on ZaBeCor Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZaBeCor Pharmaceutical.